Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533257 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Amylyx Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 11
- Study locations
NCT03533257 is a Phase 2 study of Alzheimer Disease that has completed, run by Amylyx Pharmaceuticals. The registered enrollment target is 95 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT03533257, a Phase 2 study of Alzheimer Disease, has completed, sponsored by Amylyx Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 11
- Study locations
Study Summary
The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in participants with mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMX0035
Study Locations (11)
Florida
- Clinical Neuroscience Solutions, Inc. - Jacksonville - Jacksonville
- Clinical Neuroscience Solutions, Inc. - Orlando - Orlando
- International Medical Investigational Centers (IMIC) - Palmetto Bay
New York
- Mount Sinai Alzheimer's Disease Research Center - New York
- Columbia University - New York
Illinois
- Rush University Medical Center - Chicago
Kansas
- University of Kansas Clinical Research Center - Fairway
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- Rowan University School of Osteopathic Medicine - Stratford
Pennsylvania
- Hospital of the University of Pennsylvania, Penn Memory Center - Philadelphia
Tennessee
- Genesis NeuroScience Clinic - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03533257
The ClinicalTrials.gov registry entry for NCT03533257 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Amylyx Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03533257 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Florida, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT03533257 about?
NCT03533257 is a clinical study titled "Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease". The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in participants with mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD).
What is the current status of trial NCT03533257?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2018-09-14. Estimated completion is 2020-11-06.
What conditions does trial NCT03533257 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03533257?
The interventions under investigation include: Placebo (DRUG), AMX0035 (DRUG).
Who is sponsoring clinical trial NCT03533257?
This trial is sponsored by Amylyx Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03533257 being conducted?
This trial has 11 study locations across Florida, Illinois, Kansas, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.